Jack Cope, a 30-year-old joiner from Bedford, has experienced hereditary angioedema (HAE) since birth. The condition causes severe, unpredictable swelling and painful attacks throughout his body, including his throat, stomach, and face. Even minor actions, like using a hammer, could trigger a painful swelling episode in his hand.
Cope was frequently experiencing about one attack per week before participating in a clinical trial at Addenbrooke's Hospital. He reports that the new treatment he is trialing has dramatically reduced his symptoms, leading to nearly a year without any attacks. "It's changed my life. I can do everything I want to now. It's brilliant," Cope stated.
The trial at Addenbrooke's Hospital is exploring novel therapeutic approaches for HAE, a genetic disorder characterized by recurrent episodes of swelling. While the specifics of the trial treatment are not detailed in the provided notes, Cope's significant improvement suggests a promising development for patients living with this chronic condition. HAE affects approximately 1 in 10,000 to 1 in 50,000 people worldwide, often leading to significant disruption in daily life and potential medical emergencies. The condition is caused by genetic mutations that lead to an overproduction of bradykinin, a substance that causes blood vessels to leak fluid into surrounding tissues, resulting in swelling. The unpredictable nature of HAE attacks makes it challenging to manage and can impact a patient's ability to work, socialize, and maintain a normal lifestyle. Cope's experience highlights the potential for new treatments to restore quality of life for those affected by HAE.